In 2012, a joint task force from ISPOR and SMDM produced a set of guidelines on modeling good practices for research [1] . These articles are highly influential in the field of health technology assessment, and rightly so. Therefore, we would like to discuss some concerns they raise about the definition and interpretation of an important aspect, namely, model validation [2] .
The Validation Process
The task force distinguishes models to be used once (singleapplication) from those to be used several times (multiapplication). The task force states that validation should be ongoing for a multiapplication model, while it can be conducted once for a single-application model [2] . In our opinion, however, validation should be continuous [5, 9] , regardless of the number of times a model is applied. Unfortunately, this recommendation is seldom followed [4] .
Conducting validation throughout the modeling process would be worth every effort because mistakes could then be found and corrected at an earlier stage. Validating once toward the end leaves little time to remedy any problems they produce. Furthermore, the likelihood of finding mistakes increases with the number of validation rounds, minimizing the chance that the model will contain serious errors when decisions are made on its basis. In addition, when stakeholders are continuously involved in building the model, instead of being asked for comments afterwards, they will be more inclined to accept it, because they understand its rationale. Altogether, more validation points could make model development shorter and cheaper.
While differentiating types of models for validation purposes is useful, the focus should lie on the outcomes and the decisions to be based on them, rather than on the number of times the model will be used. For example, verification examines the extent to which the mathematical calculations are performed correctly and are consistent with the model's specifications [2] . One of the most powerful verification tools is double coding, whereby some or all the code is programmed twice and independently. Although very time consuming, this yields a very high level of verification. Yet it is unlikely that the amount of time, effort, and money needed for double coding will be invested in a model with a relatively small impact, even if it is used more than once. Nonetheless, double coding may be cost-effective and perhaps even necessary for models supporting decisions with large budget impacts.
When Is a Model Valid Enough?
According to the authors of the guidelines, "it is not possible to specify criteria that a model must meet to be declared 'valid.' " This is true, though we would add that it is possible to operationalize a level of validity: a model can be "valid enough" to reliably support a decision to be based on its outcomes. In this respect, corroboration is a relevant term [10] . Passing any validation test corroborates the model and increases its credibility. One of the aims of a project we have just started is to operationalize validation guidelines by selecting tools on the grounds of their relevance. We would then add workable criteria, keeping in mind the impact of the decisions ultimately to be made on health care and budgets. A work in progress, we expect it to improve the model review process by providing an overview of validation tools applied during its development and their results in relation to the model's aim.
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Conclusions
We have proposed an alternative definition of validation because we felt that the definition proposed by the task force is not adequate for health-economic decision models. Any comments on our proposal are welcome. We have also recommended introducing validation as a continuous process in all types of models, thereby dropping the distinction between single-purpose and multiuse models. Finally, while agreeing with the task force that it may not be possible to declare a model "valid," we have added that it might be possible to call a model "valid enough" for its purpose. Introducing a continuum of validity is practically useful and should not be disregarded.
The ISPOR/SMDM Modeling Good Research Practices Task Force has assembled a state-of-the-art overview of healtheconomic decision modeling and has been rightly commended for this work. Any state of the art, however, is a moving target. Experience in other scientific fields is worth taking into account to help move the target in health-economic decision modeling, toward providing reliable support for the important policy decisions facing health care systems today.
